- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06308575
A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma
Study Overview
Status
Intervention / Treatment
Detailed Description
Primary Objective:
- To assess the efficacy of rivoceranib in patients with R/M ONB
Secondary Objective:
- To estimate the median duration of response (DOR)
- Time to response
- To estimate the median progression-free survival (PFS)
- To estimate the median overall survival (OS)
- To assess safety of rivoceranib
Tertiary Objective:
- To explore biomarkers that may predict response to therapy
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Luana Guimaraes De Sousa, MD
- Phone Number: (832) 728-7849
- Email: lgsousa@mdanderson.org
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center
-
Principal Investigator:
- Luana Guimaraes De Sousa, MD
-
Contact:
- Luana Guimaraes De Sousa, MD
- Phone Number: 832-728-7849
- Email: lgsousa@mdanderson.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants ≥18 years with histology-proven R/M ONB.
- Not amenable to curative intent surgery or radiotherapy
- Measurable disease per RECIST 1.1
- Performance status ECOG of 0 or 1
- VEGFR-inhibitor naïve (R/M ONB never treated with VEGFR inhibitors)
Laboratory measurements, blood counts:
a) Hemoglobin ≥ 9 g/dL. Red blood cell transfusions are permitted to meet the hemoglobin inclusion criteria b) Absolute neutrophil count ≥ 1 x 109
- mL c) Platelets ≥ 80 x 109
- mL
Laboratory measurements, renal function:
a) Creatinine clearance ≥ 30 mL/min as assessed by the Cockcroft-Gault equation
Laboratory measurements, hepatic function:
- AST and ALT ≤ 2.5 x ULN or ≤ 5 x ULN in subjects with liver metastases
- Total bilirubin ≤ 1.5 x ULN or ≤ 3.0 x ULN and primarily unconjugated if subject has a documented history of Gilbert's syndrome or genetic equivalent
- Female participants with reproductive potential must practice two effective contraceptive measures for the duration of study drug therapy and for at least 90 days after completion of study therapy. The two birth control methods can be either two barrier methods or a barrier method plus a hormonal method to prevent pregnancy. The following are considered adequate barrier methods of contraception: diaphragm, condom, copper intrauterine device, sponge, or spermicide. Appropriate hormonal contraceptives will include any registered and marketed contraceptive agent that contains an estrogen and/or a progestational agent (including oral, subcutaneous, intrauterine, or intramuscular agents).
- Male participants who are sexually active with women with reproductive potential must agree to use contraception for the duration of treatment and for at least 90 days after completion of study therapy.
Exclusion Criteria:
- Prior radiation therapy (or other nonsystemic therapy) within 2 weeks prior to enrollment
- Active CNS disease (participants with asymptomatic and stable, treated CNS lesions who have been off corticosteroids, radiation, or other CNS-directed therapy for at least 4 weeks are not considered active)
- Red blood cell transfusion dependence, defined as requiring more than 2 units of packed red blood cell transfusions during the 4-week period prior to screening. Red blood cell transfusions are permitted during the screening period and prior to enrollment to meet the hemoglobin inclusion criterion.
- Prior anticancer therapy including, but not limited to, chemotherapy, immunotherapy, or investigational agents within 4 weeks or 5 half-lives prior to rivoceranib treatment
- Current participation in another interventional clinical study
History of previous malignancy other than malignancy treated with curative intent within less than 5 years. Participants with the following diagnoses represents an exception and may enroll if ≥ 1 year with no evidence of active disease before the first dose of the study drug.:
- Non-melanoma skin cancers with no current evidence of disease
- Melanoma in situ with no current evidence of disease
- Localized cancer of the prostate with prostate-specific antigen of <1 ng/mL
- Treated or localized well-differentiated thyroid cancer
- Treated cervical carcinoma in situ
- Treated ductal/lobular carcinoma in situ of the breast
- Evidence of uncontrolled, active infection, requiring systemic anti-bacterial, anti-viral or anti-fungal therapy ≤ 10 days prior to administration of investigational product. Participants with known hepatitis B, hepatitis C (HCV), or HIV infection could go on study provided the viral load is undetectable at screening.
- Participants with poor-controlled arterial hypertension (systolic blood pressure > 140 mmHg and diastolic blood pressure > 90 mmHg) despite standard medical management
- Participants with Grade II or greater myocardial ischemia or myocardial infarction, uncontrolled arrhythmias (QTc interval ≥ 450 ms in males and ≥ 470 ms in females);
- Participants with NYHA (see Appendix 5) Class III-IV cardiac insufficiency or LVEF (left ventricular ejection fraction) < 50% by echocardiography;
- Presence of multiple factors affecting oral medications (such as inability to swallow, chronic diarrhea, and intestinal obstruction, which significantly affect drug administration and absorption);
- Urine protein ≥ ++ or 24 h urine protein > 1.0 g as indicated by urinalysis
- Female subjects who are pregnant or breast-feeding
- Known hypersensitivity to any of the study drugs, the metabolites, or formulation excipient
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Rivoceranib
Particpants will take rivoceranib by mouth 1 time each day while on study.
|
Given by PO
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and Adverse Events (AEs)
Time Frame: Through study completion; an average of 1 year.
|
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
|
Through study completion; an average of 1 year.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Luana Guimaraes De Sousa, MD, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Cranial Nerve Diseases
- Neuroectodermal Tumors, Primitive
- Neuroectodermal Tumors, Primitive, Peripheral
- Olfactory Nerve Diseases
- Recurrence
- Neuroblastoma
- Esthesioneuroblastoma, Olfactory
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Apatinib
Other Study ID Numbers
- 2023-0771
- NCI-2024-02155 (Other Identifier: NCI-CTRP Clinical Registry)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Olfactory Neuroblastoma
-
National Cancer Institute (NCI)RecruitingOlfactory Neuroblastoma | EsthesioneuroblastomaUnited States
-
Hongmeng YuRecruitingOlfactory NeuroblastomaChina
-
National Cancer Institute (NCI)RecruitingLocally Advanced Chondrosarcoma | Metastatic Chondrosarcoma | Metastatic Sinonasal Adenocarcinoma | Locally Advanced Sinonasal Adenocarcinoma | Metastatic Large-cell Neuroendocrine Carcinoma | Locally Advanced Large-cell Neuroendocrine Carcinoma | Metastatic Olfactory Neuroblastoma | Locally Advanced... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingOlfactory Neuroblastoma | Esthesioneuroblastoma | Neoplasm of the Nasal CavityUnited States
-
Ricardo L. Carrau, MDWithdrawnEsthesioneuroblastoma, OlfactoryUnited States
-
Eye & ENT Hospital of Fudan UniversityRecruiting
-
St. Paul's Hospital, CanadaRecruitingOlfactory DisorderCanada
-
University of Kansas Medical CenterCompleted
-
Centre Hospitalier Universitaire de NiceNot yet recruitingPatients Without an Olfactory Disorder
-
University of WashingtonCompleted
Clinical Trials on Rivoceranib
-
Elevar TherapeuticsCompleted
-
Jiangsu HengRui Medicine Co., Ltd.TerminatedAdvanced Hepatocellular Carcinoma (HCC)China
-
Elevar TherapeuticsTerminatedMetastatic Colorectal CancerUnited States
-
Elevar TherapeuticsCompletedGastric Cancer | Gastric AdenocarcinomaUnited States, United Kingdom, Korea, Republic of, France, Taiwan, Japan, Russian Federation, Germany, Italy, Poland, Romania, Ukraine
-
Elevar TherapeuticsCompletedAdenoid Cystic CarcinomaUnited States, Korea, Republic of
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruitingAdjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or AblationChina
-
Sun Yat-sen UniversityJiangsu HengRui Medicine Co., Ltd.RecruitingIntrahepatic CholangiocarcinomaChina
-
Ruijin HospitalRecruiting
-
Samsung Medical CenterNot yet recruitingThymic Epithelial TumorKorea, Republic of
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruiting